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Summary: Administration of niridazole to rats poisoned with copper caused a significant increase in both the
urinary and biliary excretion of the metal. Although the urinary excretion of iron was increased by the drug,
iron excretion was significantly decreased during the drug-induced excretion of copper after copper poisoning.
Formation of a copper-niridazole chelate or chelates before excretionjn the bile or urine may explain these
findings. Polarity and molecular weights of the metal-drug chelates formed in vivo may be the directing forces
not only in the selection of the metal for chelation, but also for its urinary or biliary excretion. The laboratory
preparation of two copper-niridazole complexes lends support to these conclusions.
Weitere Untersuchungen zur Wirkung von Niridazol auf die Ausscheidung von Kupfer in Harn und Galle
Zusammenfassung: Niridazol steigert bei mit Kupfer vergifteten Ratten die Kupferausscheidung in Harn und
Galle signifikant. Obwohl die Eisenausscheidung im Harn durch Niridazol gesteigert war, war sie während der
durch Niridazol induzierten Ausscheidung von Kupfer nach Kupfervergiftung signifikant erniedrigt. Bildung
von Kupferchelat(en) vor der Ausscheidung mit Galle oder Harn kann diese Beobachtungen erklären. Polari-
tät und Molekulargewichte der in vivo gebildeten Metallchelate können Einflußgrößen nicht nur für die
Selektion des Metalls für die Chelatbildung, sondern auch für seine Ausscheidung mit Harn oder Galle sein.
Die Präparation von zwei Kupfer-Niridazolkomplexen im Laboratorium unterstützt unsere Schluß-
folgerungen.
Introduction
In earlier studies, the antibilharzial drug, niridazole
(ambilhar), was shown to have the property of ligat-
ing or chelating iron. Salah et al. (1) and Abdel Aziz
et al. (2) demonstrated the excretion of iron in the
urine of man and animals during administration of
the drug. Similar effects of niridazole on body calci-
um and magnesium (3) and leäd (4) were reported.
The later findings on lead excretion were explained
by the forrnation of a lead-niridazole complex in vi-
vo, which resulted in lead mobilization and excre-
tion.
Later, Abdel Aziz et al. (5) reported that niridazole
stimulated the biliary excretion of mercury in rats.
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This finding was explained by the formation of a po-
lar complex with mercury of a higher molecular
weight, which undergoes biliary rather than urinary
excretion.
D-Penicillamine is an orally administered chelating
agent used mainly in Wilson's disease. It increases
the urinary outpüt of copper more than 5 times com-
pared with that of untreated cases. It was found that
D-penicillamine gives rise to some undesirable ef-
fects (6).
The aim of this study is to investigate the effect of
niridazole on the excretion of copper, which could be
useful clinically in copper storage diseases. Also the
effect of niridazole on body iron excretion under
these conditions seems important.
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Materials and Methods
In v ivo e x p e r i m e n t s
A total of 18 Wistar albino rats, average weight 200-250 g were
used for this study. They were fed a commercial diet prepared in
the College animal house.
The animals were classified into three equal groups of 6 animals.
Group A were used äs control, while group B were dosed with
niridazole orally in a dose level of 5 mg/d. Group C animals were
poisoned with copper. A total daily dose of 4 mg copper was ad-
ministered orally to each animal for 7 successive days.
A d m i n i s t r a t i o n of n i r i dazo l e a f t e r copper po i son ing
Ambilhar (niridazole or nitrothiazole) was mixed with two kilo-
grams of the same diet, so that each gram contained about 0.5 mg
of the drug.
Administration of the drug was continued for 7 days, starting just
after the last day of copper poisoning. The urine and faecal matter
of each group was separately collected for analysis of iron and
copper.
Es t ima t ion of the copper and iron contents of u r ine
and faeces
A suitable weight of the dried faecal matter (5 g) of each group
was pulverized in a.morter with 5ml (300g/kg) HC1 (analar),
then gently heated over a direct flame for 30 minutes at 100 °C. It
was left to cool for 24 hours at 4 °C. Filtration gave a clear filtrate,
which used for the analysis. Usirtg this filtrate or 5 ml urine, cop-
per and iron were measured with the atomic absorption spectro-
photometer (Perkin-Elmer 503) (7).
A Standard solution of copper and iron containing 5 mg/1 of each
was prepared. A working Standard solution was prepared by mix-
ing equal volumes of both Standards.
Serial dilutions of this working Standard containing 2.5, 5, 7.5, 10
and 12.5 ng were used for preparing the Standard curve.
I n v i t ro expe r imen t s
To three equal fractions (l mmol each = 214 mg) of pure crystal-
line niridazole (Ciba-Geigy product) in three separate beakers
0.5, l and 2 mmol copper were added respectively (anhydrous
copper carbonate, BDH). To each beaker 2 grams sodium
metabisulphite (BDH) and 25 ml distilled water were added. The
whole mixture was left for 48 hours at 70 °C in an oven. A dark
crystalline compound was precipitated. This was filtered, washed
with ethanol (900 ml/l) followed by distilled water (three times
5 ml each), then crystallized from hot glacial acetic acid. Paper
chromatography of the acetic acid solution of the second and third
fractions (solvent System: methanol-acetic acid, 6 + l by vol.)
showed one spot from each fraction, Rf 0.3 and 0.5 respectively.
About 10 mg samples of each of these two fractions were submit-
ted for determination of molecular weights and copper contents.
The results are shown in table 2.
Results and Discussion
It is clear from table l that the urinary excretion of
copper during administration of niridazole is signifi-
cantly incrased. This finding can be explained by a
possible chelation of the drug with copper followed
by excretion. Evidence for such chelation is found in
previous studies on the effect of the drug on excre-
tion of other metals by chelation (1—4). Also iron
excretion was significäritly increased under these
conditions.
Unlike iron, copper was also excreted in the bile äs
well äs the urine. However, the major route föf its
excretion during drug administration was found to
be urinary. It is also clear that in nifidäzole-tfeated
animals after poisoning with copper, there is a biliary
excretion öf copper amounting to 50% of that ex-
cr'eted in the urine. This finding can be explained by
the higher rnolecular weight of the df ug-copper corm
plex formed in vivo (8, 9), which undergoes biliary
excretion. Preparation in vitro of two niridazole-
copper complexes with different molecular weights
could be evidence for similar in vivo metabolic be-
haviöur. Under these conditions one of the corm
plexes (higher molecular weight) undergoes biliary
excretion, while the other (lower molecular weight)
is excreted in the urine,
The sarne table shows a relationship between copper
and iron excretion. Increased copper excretion by
the drug was accompanied by a significant decrease
of iron excretion i.e., in niridazole-treated animals
after intoxication with copper, the reduction in uri-
nary iron excretion was about 50%, arid the decrease
in biliary iron excretion was found to be about 13%.
The metabolic behaviour of both copper and iron is
affected by the drug. Before poisoning with copper
the drug caused a significant decrease in copper bil-
iary excretion with a concomitant increase in its uri-
nary Output. After poisonirig with copper the drug
increased the biliary excretion of copper significant^
Tab. 1. Effect of niridazole on the urinary and biliary excretion of copper and iron in Wistar albino rats (mg/week).
Groupof rats
1. Control animals
2. Niridazole dosed animals
3. Niridazole dosed animals after poisoning with copper
Copper
Urine
0.039
±(0.001)
0.073**
±(0.005)
0.756**
±(0.05)
Bile
0.292
±(0.016)
' 0.051**
±(0.003)
0.371**
±(0.01)
Iron
Urine
0.337
±(0.014)
0.962**
±(0.12)
0.467**
±(0.055)
Bile
0.490
±(0.017)
0.238**
±(0.01)
0.282**
±(0.015)
* Significant at 5% probability.
** Significant at 1% probability.
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ly. Under these conditions the drug caused a marked
decrease in biliary excretion of iron, which can be
explained by the higher chelating power of nirida-
zole for copper than for iron (in vivo), forming a
higher molecular weight complex which undergoes
biliary excretion (8, 9). Table 2 shows the results of
our in vitro experiments.
Tab. 2. Copper content, molecular weight and chelation ratio of
the two copper-niridazole complexes prepared in vitro.
Complex
Complex 1
Complex 2
Copper
(fraction)
0.2545
0.4083
Molecular
weight
249.5
311
Chelation ratio
copper: niridazole
1 : 1
2: 1
H2N NH
sCu-
Fig. 1. Proposed structure of niridazole copper complex I. The
copper content is 25.45%. The molecular weight is 249.5.
It was prepared in vitro by mixing copper carbonate with
niridazole in the presence of sodium metabisulphite.
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Finally, this study not only adds to the existing evi-
dence for the chelating power of niridazole with ca-
tions and its selective property in the process of liga-
tion, but also suggests its value äs a selective drug in
copper storage diseases.
Fig. 2. Proposed structure of niridazole copper complex II. The
copper content is 40.83%. The molecular weight is 311. It
was prepared in vitro by mixing copper carbonate (double
the amount in complex I) with the same amount of nirida-
zole in the presence of sodium metabisulphite.
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